A ginsenoside liposome encapsulating soluble collagen, and a preparation method and application thereof

Abstract

The present application relates to a ginsenoside liposome wrapped with soluble collagen, a preparation method and application thereof, and belongs to the field of daily chemicals. The ginsenoside liposome wrapped with soluble collagen according to the present application comprises 0.001-0.1 parts of soluble collagen and 0.2-2 parts of supramolecular rare ginsenoside crystals by mass fraction. The supramolecular rare ginsenoside crystals comprise diol-type rare ginsenoside, triol-type rare ginsenoside and supramolecular plant fermentation liquor. The mass ratio of the diol-type rare ginsenoside, the triol-type rare ginsenoside and the supramolecular plant fermentation liquor is (0.01-10):(0.01-10):(0.1-20). The liposome of the present application is compounded by the soluble collagen and the supramolecular rare ginsenoside crystals, which can not only inhibit the activity of 5-alpha reductase, but also reduce the transdermal water loss and inhibit the secretion of oil, and has significant effects of preventing hair loss, repairing and controlling oil.

Description

Technical Field

[0001] This invention belongs to the field of daily chemical products, specifically relating to a ginsenoside liposome encapsulating soluble collagen, its preparation method, and its application. Background Technology

[0002] With social development and improved living standards, people are paying more and more attention to their hair. However, hair loss has become a common problem troubling many people. It is understood that more than half of men and one-third of women worldwide experience hair loss at some point in their lives, which seriously affects their quality of life and self-confidence. The causes of hair loss differ between men and women. Male pattern baldness is mainly caused by genetic factors, stress, androgens, and excessive sebum secretion. Female pattern baldness is caused by hormonal changes, hair damage, excessive pulling, stress, weight loss, and endocrine disorders.

[0003] To address this issue, numerous hair loss prevention products and technologies have emerged on the market, including anti-hair loss shampoos and conditioners, medications, hair transplants, and hair transplant techniques. Anti-hair loss shampoos and conditioners primarily contain plant extracts such as ginger and tea tree oil, believed to promote hair growth, enhance hair elasticity, and improve scalp health. For example, patent CN110731922A provides an enhanced anti-hair loss and hair growth composition containing concentrated birch sap and one or more of the following: ginger extract, Polygonum multiflorum root extract, ginseng extract, green tea extract, Platycladus orientalis extract, Angelica sinensis extract, Astragalus membranaceus, Eclipta prostrata, birch bud extract, birch leaf extract, adenosine, nicotinamide, and tripeptide-1 copper. It has been found that the combination of birch sap and various plant extracts has an anti-hair loss effect. Furthermore, medications are currently the most common treatment for hair loss, such as minoxidil and finasteride. These drugs can slow down or prevent hair loss by influencing androgen levels and promoting hair growth. However, these drugs also have certain side effects and limitations and cannot be used long-term. However, hair transplantation and hair restoration techniques are relatively expensive and technically challenging, making them unaffordable for many consumers.

[0004] Therefore, finding a safer, more effective, and cheaper anti-hair loss product has become an important research direction. Summary of the Invention

[0005] The purpose of this invention is to overcome the problems existing in the prior art and provide a ginsenoside liposome encapsulating soluble collagen with anti-hair loss, repair and oil control effects, as well as its preparation method and application.

[0006] This invention is achieved through the following technical solution:

[0007] This invention provides a ginsenoside liposome encapsulating soluble collagen, comprising, by weight, 0.001-0.1 parts soluble collagen and 0.2-2 parts supramolecular rare ginsenoside crystals;

[0008] The supramolecular rare ginsenoside crystals comprise diol-type rare ginsenosides, triol-type rare ginsenosides, and supramolecular plant fermentation broth; the mass ratio of the diol-type rare ginsenosides, triol-type rare ginsenosides, and supramolecular plant fermentation broth is (0.01-10):(0.01-10):(0.1-20).

[0009] The preparation method of the supramolecular plant fermentation broth includes the following steps: inactivating the fermentation broth obtained by fermentation culture of lactobacillus or the wet bacterial cells obtained by fermentation centrifugation, centrifuging to obtain supernatant, adding plant extract and supramolecular NaDES solvent to the obtained supernatant, heating and stirring until the solution is clear, and cooling to obtain the final product.

[0010] The soluble collagen used in the ginsenoside liposomes encapsulating soluble collagen in this invention is also known as recombinant collagen, a non-hydrolyzed native protein derived from the connective tissue of young animals. Soluble collagen has a smaller molecular weight than conventional collagen, making it easier for the body to absorb and utilize. It is widely believed to promote skin elasticity and moisture content, improving dry skin and wrinkles. Furthermore, soluble collagen is also thought to promote wound healing and a healthy immune system. Diol-type rare ginsenosides include Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rg5, Rh2, Rh3, F2, CK, etc. Among them, Rg3 can provide comprehensive skin care effects such as anti-aging, inhibiting UV-induced skin damage, significantly inhibiting melanin synthesis, inducing M2 polarization of macrophages and accelerating the resolution of inflammation; Rh2 has the effects of anti-photoaging and inhibiting the proliferation of melanoma B16 cells; Rg5 can block the binding of IGF-1 to its receptor, inhibit the DNA binding activity of NF-κBp65 to inhibit COX-2 mRNA expression, activate the MEK-ERK signaling pathway, and has whitening and anti-inflammatory effects. Triol-type rare ginsenosides include Re, Rg1, Rf, Rg2, Rg4, Rh1, Rh4, and a small amount of oleanolic acid saponin Ro. Among them, Rg2 can protect cells by increasing DNA repair, regulate the protein levels involved in the p53 signaling pathway, build endogenous homeostasis, and maintain cell homeostasis. It can also protect against H2O2-induced cell damage and apoptosis through antioxidant and anti-apoptotic effects, significantly repair cell morphology, and reduce apoptosis. Rh1 can inhibit the expression of PPAR-γ, TNF-α, IL-6, and IL-1β, and has effective properties such as anti-inflammatory, antioxidant, immunomodulatory, and positive effects on the nervous system. Rk3 can significantly inhibit TNF-α-induced NF-κB transcriptional activity and plays an important role in inhibiting photoaging and inflammation and protecting skin health. Rh4 can enhance autophagy and regulate apoptosis, and has photoaging, inhibitory, and antifungal activities. The supramolecular structure refers to a supramolecular structure formed by adding a supramolecular solvent to a solution and assembling through intermolecular forces (including hydrogen bonds, van der Waals forces, π-π stacking, and electrostatic interactions). Among these, hydrogen bonds, due to their high strength, directionality, saturation, and diverse bonding modes, are the most important supramolecular force in eutectic formation. The overall structure of ginsenosides shows that they possess a hydrophilic and lipophilic structure, exhibiting certain surfactant properties and encapsulation capabilities. Furthermore, the addition of a certain amount of supramolecular plant fermentation broth allows the surfactant to be stabilized at the encapsulation emulsion interface through intermolecular forces due to its own hydrogen bonding, thereby enhancing the formation of encapsulated liposomes.The supramolecular rare ginsenoside crystals selected in this invention are obtained by mixing and compounding diol-type and triol-type rare ginsenosides with supramolecular plant fermentation broth. Through the hydrophilic and lipophilic structure of the ginsenoside surface and the hydrogen bonding of the supramolecular plant fermentation broth, the resulting ginsenoside liposomes exhibit excellent encapsulation effects on soluble collagen, forming a stable encapsulation structure. The liposomes of this invention, through the compounding of soluble collagen and supramolecular rare ginsenoside crystals, can not only inhibit 5-α reductase activity but also reduce transdermal water loss and inhibit sebum secretion, exhibiting significant anti-hair loss, repair, and oil control effects.

[0011] Preferably, in the preparation method of the supramolecular plant fermentation broth, the inactivation temperature is 60℃-80℃, and the heating and stirring temperature is 70℃-90℃.

[0012] Preferably, the supramolecular NaDES solvent comprises 0.1-10 parts lactobionic acid, 0.1-10 parts fructose, 0.1-10 parts sorbitol, and 0.5-50 parts water; the supramolecular NaDES solvent is prepared by heating lactobionic acid, fructose, sorbitol, and water at 46℃-50℃ for 2.5h-3.5h and drying at 58℃-62℃ for 71h-73h according to the stated mass parts.

[0013] As a preferred embodiment of the ginsenoside liposomes encapsulating soluble collagen described in this invention, the supramolecular plant fermentation broth includes at least one of supramolecular rose fermentation broth, supramolecular oat fermentation broth, and supramolecular peony fermentation broth.

[0014] In a preferred embodiment of the ginsenoside liposomes encapsulating soluble collagen described in this invention, the soluble collagen is type XVII collagen; and the supramolecular plant fermentation broth is supramolecular peony fermentation broth.

[0015] Soluble collagen is classified into type I, type III, type V, type VI, and type XVII. The lack of type XVII collagen can lead to rapid loss of hair follicles. As age increases, type XVII collagen is continuously lost, and hair follicles will naturally atrophy. Therefore, this invention prefers type XVII collagen as the soluble collagen.

[0016] Preferably, the preparation method of the supramolecular peony fermentation broth is as follows: the fermentation broth obtained by fermentation culture of lactobacillus or the wet bacterial cells obtained by fermentation centrifugation are inactivated, centrifuged to obtain supernatant, peony extract and supramolecular NaDES solvent are added to the obtained supernatant, heated and stirred until the solution is clear, and cooled to obtain the broth; the peony extract includes peony branch extract, peony flower extract and peony leaf extract, and the mass ratio of the peony branch extract, peony flower extract and peony leaf extract is (6-10):(0.5-2):(0.5-2).

[0017] More preferably, the mass ratio of the peony branch extract, peony flower extract, and peony leaf extract is 8:1:1.

[0018] As a preferred embodiment of the ginsenoside liposomes encapsulating soluble collagen according to the present invention, the ginsenoside liposomes encapsulating soluble collagen comprises, by weight, 0.05-0.1 parts of soluble collagen and 1.2-2 parts of ginsenoside liposomes.

[0019] In a preferred embodiment of the ginsenoside liposomes encapsulating soluble collagen described in this invention, the mass ratio of the diol-type rare ginsenosides, the triol-type rare ginsenosides, and the supramolecular plant fermentation broth is (1-7):(1-7):(0.1-20); preferably, the mass ratio of the diol-type rare ginsenosides, the triol-type rare ginsenosides, and the supramolecular plant fermentation broth is 3:7:(0.1-20).

[0020] As a preferred embodiment of the ginsenoside liposomes encapsulating soluble collagen described in this invention, in the method for preparing the supramolecular plant fermentation broth, the mass ratio of the supernatant, plant extract and supramolecular NaDES solvent is (1-30):(7-14):(1-30).

[0021] Another object of the present invention is to provide a method for preparing the above-mentioned ginsenoside liposomes encapsulating soluble collagen, comprising the following steps:

[0022] (1) Mix diol-type rare ginsenosides, triol-type rare ginsenosides and supramolecular plant fermentation liquid, heat and dry to obtain supramolecular rare ginsenoside crystals.

[0023] (2) The supramolecular rare ginsenoside crystals obtained in step (1) are mixed and dissolved with soluble collagen, and then rotary evaporated to obtain a thin film;

[0024] (3) Add the buffer solution to the film obtained in step (2) to form a liposome suspension. Homogenize under high pressure to obtain the ginsenoside liposomes encapsulating soluble collagen.

[0025] The preparation method of this invention is simple and can form ginsenoside liposomes that stably encapsulate soluble collagen with good encapsulation effect.

[0026] Preferably, in step (1), the heating temperature is 70℃-90℃ and the time is 5h-7h; the drying temperature is 120℃-150℃ and the time is 48h-72h.

[0027] Preferably, in step (3), the buffer solution is a phosphate buffer solution; the concentration of the phosphate buffer solution is 0.05 mol / L and the pH is 6.5; the pressure of the high-pressure homogenization is 120 MPa.

[0028] In the preparation method of this invention, the addition of buffer solution can maintain the osmotic pressure and pH balance of liposomes.

[0029] Preferably, in step (3), the amount of phosphate buffer added is 10%-25% of the total mass of supramolecular rare ginsenoside crystals and soluble collagen.

[0030] Another object of the present invention is to provide the application of the ginsenoside liposomes encapsulating soluble collagen in cosmetics.

[0031] Preferably, the dosage form of the cosmetic includes any one of aqueous solution, lotion, or cream.

[0032] Applying the ginsenoside liposomes containing soluble collagen as described in this invention to cosmetics can give the cosmetics excellent anti-hair loss, oil control and repair effects.

[0033] Another object of the present invention is to provide an extract comprising ginsenoside liposomes encapsulating soluble collagen, wherein the ginsenoside liposomes encapsulating soluble collagen constitute 1%-10% by mass in the extract; preferably 5%-10%.

[0034] The present invention has the following beneficial effects: The ginsenoside liposomes of the present invention, which encapsulate soluble collagen, utilize the hydrophilic and lipophilic structure of the ginsenoside surface and the hydrogen bonding effect of the supramolecular plant fermentation broth to achieve excellent encapsulation of soluble collagen, forming a stable encapsulation structure. Furthermore, the ginsenoside liposomes of the present invention have good encapsulation effect, small particle size, and can easily penetrate deep into the skin to exert higher efficacy. Through the synergistic effect between components, the ginsenoside liposomes of the present invention have excellent inhibitory activity of 5-α reductase, effectively preventing hair loss. Simultaneously, the liposomes of the present invention also have oil-controlling and repairing effects, comprehensively improving hair and scalp health. Detailed Implementation

[0035] To better illustrate the objectives, technical solutions, and advantages of this invention, the invention will be further described below with reference to specific embodiments. Those skilled in the art should understand that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.

[0036] Unless otherwise specified, the experimental methods used in the examples are conventional methods; the materials and reagents used are commercially available unless otherwise specified.

[0037] Examples and Comparative Examples

[0038] The components and weight parts of the ginsenoside liposomes encapsulating soluble collagen in the embodiments and comparative examples of the present invention are shown in Tables 1-2 below. The preparation method of the ginsenoside liposomes encapsulating soluble collagen includes the following steps:

[0039] (1) The diol-type rare ginsenosides, triol-type rare ginsenosides and supramolecular peony fermentation liquid were mixed and heated to 80°C for 6 hours to obtain a supramolecular eutectic of rare ginsenosides. The mixture was placed in an oven at 135°C for 60 hours and then naturally cooled to room temperature to obtain supramolecular rare ginsenoside crystals.

[0040] (2) The supramolecular rare ginsenoside crystals obtained in step (1) and soluble collagen (type XVII collagen) are mixed according to the mass fractions described in Table 1 and Table 2. Under the condition of 45°C water bath, 1g of supramolecular rare ginsenoside crystals are dissolved in 15mL of anhydrous ethanol to ensure that all components are completely dissolved. Then, the anhydrous ethanol is removed under reduced pressure on a rotary evaporator to obtain a film.

[0041] (3) Add 0.05M phosphate buffer solution at pH 6.5 to the film obtained in step (2) (the percentage of the amount of phosphate buffer solution added to the total mass of supramolecular rare ginsenoside crystals and soluble collagen is shown in Table 1 and Table 2) to form a pale yellow liposome suspension. The liposome suspension is treated with a high-pressure microfluidic homogenizer at a pressure of 120 MPa for 2 times to obtain the ginsenoside liposomes encapsulating soluble collagen.

[0042] The preparation method of supramolecular peony fermentation broth is as follows: the fermentation broth obtained by fermenting Lactobacillus is inactivated at 70℃, the supernatant is collected by centrifugation, and then peony extract and supramolecular NaDES solvent (lactobacic acid, fructose, sorbitol and water in a molar ratio of 1:1:1:5, heated at 48℃ for 3 hours and dried at 60℃ for 72 hours to obtain supramolecular NaDES solvent) are added to the supernatant. The mixture is heated and stirred at 80℃ until the solution is clear, and then cooled to obtain supramolecular peony fermentation broth. After passing the test, the broth is discharged. The peony extract is composed of peony branch extract, peony flower extract and peony leaf extract in a mass ratio of 8:1:1. The mass ratio of the supernatant, peony extract and supramolecular NaDES solvent is 15.5:10.5:15.5.

[0043] Table 1. Content of each component in the liposomes of the examples (parts)

[0044]

[0045] Table 2 shows the content of each component in the liposomes of the comparative example.

[0046]

[0047]

[0048] The preparation method of ginsenoside liposomes encapsulating soluble collagen in Comparative Example 1 differs from the other examples and comparative examples in that, instead of adding supramolecular peony fermentation broth, an equal amount of deionized water is used to replace the supramolecular peony fermentation broth, while the other steps are the same.

[0049] Example of effect

[0050] 1. Stability Testing

[0051] Test method: The ginsenoside liposomes containing soluble collagen in the examples and comparative examples were centrifuged at 3000 rpm for 30 min, and their separation was observed to test their stability; the results are shown in Table 3.

[0052] 2. Encapsulation efficiency test

[0053] Test method: Take 1 mL of each of the ginsenoside liposomes encapsulating soluble collagen from the examples and comparative examples, centrifuge (18000 r / min, 30 min, 3 times, 30 min interval each time), discard the supernatant, and wash the liposome precipitate three times with 1 mL of distilled water each time. Combine the supernatants and place them in a 25 mL volumetric flask, then dilute to volume with deionized water. HPLC analysis shows the concentration of soluble collagen as V1. Separately, take 1 mL of each of the ginsenoside liposomes encapsulating soluble collagen from the examples and comparative examples, place them in a 25 mL volumetric flask, dilute to volume with deionized water, and analyze the concentration of soluble collagen as V0 using HPLC. Encapsulation efficiency % = (V0 - V1) / V0 × 100%; the results are shown in Table 3.

[0054] 3. Particle size test:

[0055] Experimental principle: The laser particle size analyzer tests particle size distribution based on the physical phenomenon that particles can cause laser light to scatter.

[0056] Experimental procedure: Dissolve 1 gram of the sample to be tested in 300 ml of deionized water to prepare a solution. Before detection, use the ultrasonic device equipped with the laser particle size analyzer to sonicate the solution to be tested. Each sample is subjected to 3 pretreatment ultrasonic treatments with an interval of 1 minute between each treatment. After ultrasonic treatment, the particle size is measured 3 times and the average value of the 3 test data is taken. The results are shown in Table 3.

[0057] 4.5-α reductase test

[0058] Experimental principle: 5-α reductase is a membrane protease located on microsomes and the cell nucleus. It uses nicotinamide adenine dinucleotide as a substrate hydrogen donor to catalyze the conversion of testosterone to dihydrotestosterone (DHT). It is mainly distributed in the liver, sebaceous glands, and hair follicles. It plays an important role in the pathological process of converting testosterone in hair follicles into DHT, which leads to seborrheic alopecia. Therefore, an important indicator for verifying hair loss is to verify the inhibition rate of 5-α reductase.

[0059] Experimental procedure: The test samples were prepared into 20% solutions with deionized water. Testosterone was used as the substrate and finasteride as the positive control. The results were analyzed by high performance liquid chromatography. The change in testosterone concentration before and after the reaction was tested, and the inhibition rate of the test samples on 5-α reductase was calculated. The results are shown in Table 3.

[0060] Table 3. Test results of liposomes in the examples and comparative examples.

[0061]

[0062]

[0063] As can be seen from the stability test results in Table 3, the NADES solvent in the supramolecular peony fermentation broth of this invention forms a compound network through a large number of hydrogen bonds, exhibiting a NOE effect between the participating molecules, which stabilizes the surfactant on the encapsulation emulsion interface, thereby stabilizing the liposomes, enhancing their encapsulation ability, and exhibiting good stability.

[0064] Table 3 shows that the encapsulation efficiency of supramolecular rare ginsenoside liposomes is higher than that of ordinary rare ginsenoside liposomes (Comparative Example 1). This indicates that the supramolecular peony fermentation broth can enhance the encapsulation efficiency of its liposomes through intermolecular forces, resulting in more stable encapsulation. This is because rare ginsenosides are lipid-soluble substances. Under the intermolecular interaction of supramolecular molecules, the lipophilic groups extend upwards, while the hydrophilic groups bind downwards, keeping both the hydrophilic and lipophilic ends in a long-term stable equilibrium, thus stabilizing the encapsulated liposome structure.

[0065] The particle size test results of Examples 1-5 and Comparative Examples 2-3 in Table 3 show that the ratio of diol-type and triol-type rare ginsenosides affects the particle size of liposomes. The higher the proportion of diol-type rare ginsenosides, the larger the particle size of the liposomes formed. When the ratio of diol-type rare ginsenosides to triol-type rare ginsenosides is 3:7, the average particle size of the formed liposomes is the smallest. The smaller the average particle size, the easier it is to penetrate into the deep layers of the skin, and the easier it is to exert its efficacy. The particle size test results of Examples 2, 6-7 and Comparative Examples 4-5 show that the amount of supramolecular peony fermentation broth also affects the particle size and encapsulation efficiency. Within the mass ratio range of the present invention, the average particle size of the liposomes is small, basically less than 100 nm, which makes it easier to penetrate into the deep layers of the skin and exert a higher efficacy.

[0066] The inhibition results of 5-α reductase in Table 3 show that the higher the content of rare ginsenosides encapsulating type XVII collagen, the better their effect on inhibiting 5-α reductase. However, the results of Example 2 and Comparative Examples 6 and 7 show that the rare ginsenoside liposomes without encapsulating type XVII collagen and the rare ginsenoside liposomes encapsulating conopeptides of the same type of small molecule have relatively insignificant effects on inhibiting 5-α reductase.

[0067] Application examples

[0068] The ginsenoside liposomes encapsulating soluble collagen from Example 11 were made into an essence to obtain Application Examples 1-3. The ginsenoside liposomes encapsulating soluble collagen from Comparative Example 7 were also made into an essence to obtain Application Comparative Examples 1-3. Their anti-hair loss, repair, and oil control effects were tested. The content of each component in the essence is shown in Table 4.

[0069] Table 4. Essence component content (%) in application examples and comparative examples

[0070]

[0071]

[0072] The preparation methods of the extracts in application examples and comparative examples are as follows:

[0073] 1. Clean and disinfect the emulsification pot. Add the A phase raw materials into the emulsification pot in sequence, homogenize appropriately until there are no obvious large particles, stir and heat to 80℃-85℃ to make the material into a transparent material with a certain consistency, and keep it warm for 30 minutes.

[0074] 2. When the temperature drops to 40℃-45℃, add phase B raw material and stir evenly to make the material a colorless and transparent liquid; take a sample for observation. After all the physical and chemical indicators are qualified, filter the material through a 200-mesh filter cloth.

[0075] (I) Anti-hair loss test

[0076] Experimental principle: To achieve the goal of improving or preventing hair loss and maintaining a certain amount of hair through the use of anti-hair loss cosmetics, this study objectively evaluates the efficacy of anti-hair loss cosmetics by controlling various factors that affect hair loss as much as possible and selecting comparable and repeatable quantitative indicators such as hair loss count and hair density before and after using the cosmetics.

[0077] Experimental Procedure: Seventy volunteers aged 20-60 with obvious alopecia areata, total alopecia, or baldness were randomly selected and divided into 7 groups of 10 each. Volunteers were not allowed to wash their hair within 48 hours prior to the test and were not allowed to comb their hair on the morning of the visit. Upon arrival at the laboratory, volunteers were required to sit quietly for 30 minutes in an environment with a temperature of 20±2℃ and a relative humidity of 50±10%RH. Each time, the same trained technician used a comb of the same specifications (6-7 teeth / cm) and combed the hair in the order from left front to left back and right front to right back. The hair was washed 30 times, and the number of hairs lost (T0) was recorded. Then, every other night, after washing the hair with the same shampoo and patting dry with a towel, the test sample was applied to the scalp. After massaging for 3-5 minutes to promote scalp blood circulation, the hair was dried with a hairdryer. After three months of continuous use, the hair was combed in the same way with the same comb (the hair could not be combed in the morning of the test), and the number of hairs lost (T1) was recorded. The hair loss prevention rate was calculated as (T1-T0) / T0×100%. The test results are shown in Table 5.

[0078] (II) Repair Test

[0079] Experimental principle: By measuring the water vapor pressure gradient on the skin surface, the extent of moisture loss is indicated, thus reflecting the skin's water permeability barrier. When the barrier function is impaired, the TEWL value increases; conversely, a decrease in TEWL indicates barrier repair.

[0080] Experimental Procedure: Seventy volunteers aged 20-45 with sensitive skin exhibiting some facial redness and a baseline transepidermal water loss (TEWL) value >12g / mg2h were randomly divided into seven groups of 10 participants each. After cleansing their faces morning and evening, volunteers applied an appropriate amount of the product to their entire face. No other cosmetics or medications were applied to their faces during the trial period. The product was used continuously for 28 days. The change rate of the skin's TEWL value before and after using the product was assessed using a CK multifunctional skin analyzer (Germany) to determine the product's repair effect.

[0081] TEWL value change rate = [(after using sample - before using sample) / before using sample] × 100%; the test results are shown in Table 5.

[0082] (III) Oil Control Test

[0083] Experimental principle: The amount of oil on the skin surface is measured by measuring the transparency of the oil-absorbing tape after it absorbs sebum.

[0084] Experimental Methods: Eighty volunteers with oily or combination skin, aged 20-40, were randomly divided into 8 groups of 10 each. Each group applied a different test sample, with one group serving as a blank control and receiving no product. Volunteers first washed their foreheads with an alkaline soap-based facial cleanser, rinsed thoroughly with water, and then patted their foreheads dry with lint-free absorbent paper towels. They then sat quietly for 30 minutes in an environment with a temperature of 20-22℃ and humidity of 40-60%, without drinking water or beverages, remaining relaxed and not touching their foreheads. The CK oil content tester's SM815 probe was then used to measure sebum secretion at different locations on the forehead. Measurements were taken three times, and the average value was used as the initial value, calculated to be (2.0±0.1) mg / m³. 3 The sample was evenly applied to the designated area of ​​the forehead using a silicone finger cot. After application, the patient sat still and the sebum secretion was measured for 6 hours. Measurements were taken three times at different locations, and the average value was calculated to determine the inhibition rate of sebum secretion on the skin surface. The test results were evaluated. The CK oil content probe SM815 was used to detect skin sebum content; the lower the measured value, the lower the skin sebum content. Inhibition rate = [(after use - before use) / before use] × 100%; the test results are shown in Table 5.

[0085] Table 5 shows the results of serum effect tests in application examples and comparative examples.

[0086]

[0087]

[0088] Table 5 shows that rare ginsenoside liposomes encapsulating type XVII collagen have a stronger effect on inhibiting hair loss and can more significantly reduce transepidermal water loss, indicating that they have a stronger barrier repair effect. At the same time, they can significantly inhibit the amount of sebum secreted by the skin, thus achieving an oil control effect.

[0089] In summary, the ginsenoside liposomes encapsulating soluble collagen provided by this invention can not only inhibit 5-α reductase and prevent hair loss, but also reduce transdermal water loss and inhibit sebum secretion, thus achieving the effects of preventing hair loss, repairing and controlling oil.

[0090] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. A ginsenoside liposome encapsulating soluble collagen, characterized in that, By weight, it includes 0.001-0.1 parts of type XVII collagen and 0.2-2 parts of supramolecular rare ginsenoside crystals; The supramolecular rare ginsenoside crystals are composed of diol-type rare ginsenosides, triol-type rare ginsenosides, and supramolecular peony fermentation broth; the mass ratio of the diol-type rare ginsenosides, triol-type rare ginsenosides, and supramolecular peony fermentation broth is (3-7):(3-7):(0.1-20). The preparation method of the supramolecular peony fermentation broth includes the following steps: inactivating the fermentation broth obtained by fermentation culture of lactobacillus or the wet bacterial cells obtained by fermentation centrifugation, centrifuging to obtain supernatant, adding peony extract and supramolecular NaDES solvent to the obtained supernatant, heating and stirring until the solution is clear, cooling, and thus obtaining the product; The peony extract includes peony branch extract, peony flower extract and peony leaf extract; the mass ratio of the peony branch extract, peony flower extract and peony leaf extract is (6-10):(0.5-2):(0.5-2).

2. The ginsenoside liposomes encapsulating soluble collagen according to claim 1, characterized in that, By weight, the ginsenoside liposomes encapsulating soluble collagen include 0.05-0.1 parts of type XVII collagen and 1.2-2 parts of supramolecular rare ginsenoside liposomes.

3. The ginsenoside liposomes encapsulating soluble collagen according to claim 1, characterized in that, The mass ratio of the diol-type rare ginsenosides, triol-type rare ginsenosides, and supramolecular peony fermentation broth is 3:7:(0.1-20).

4. The ginsenoside liposomes encapsulating soluble collagen according to claim 1, characterized in that, In the preparation method of the supramolecular peony fermentation broth, the mass ratio of the supernatant, peony extract and supramolecular NaDES solvent is (1-30): (7-14): (1-30).

5. A method for preparing ginsenoside liposomes encapsulating soluble collagen as described in any one of claims 1-4, characterized in that, Includes the following steps: (1) Mix diol-type rare ginsenosides, triol-type rare ginsenosides and supramolecular peony fermentation broth, heat and dry to obtain supramolecular rare ginsenoside crystals; (2) The supramolecular rare ginsenoside crystals obtained in step (1) and type XVII collagen were mixed and dissolved, and then rotary evaporated to obtain a thin film; (3) Add the buffer solution to the film obtained in step (2) to form a liposome suspension. Homogenize under high pressure to obtain the ginsenoside liposomes encapsulating soluble collagen.

6. The use of the ginsenoside liposomes encapsulating soluble collagen as described in any one of claims 1-4 in the preparation of hair and scalp care cosmetics.

7. An extract comprising ginsenoside liposomes encapsulating soluble collagen as described in any one of claims 1-4, characterized in that, The ginsenoside liposomes encapsulating soluble collagen constitute 1%-10% of the mass percentage of the essence.

Images